Form 4: Emergent BioSolutions SVP, Bioservices, William Hartzel, Reports Acquisition of Employee Stock Options
SEC Form 4 Filing
William Hartzel, SVP, Bioservices at Emergent BioSolutions, reports the acquisition of 125,000 employee stock options.
Summary
- On March 13, 2024, William Hartzel, SVP, Bioservices at Emergent BioSolutions Inc., reported a transaction involving derivative securities.
- Hartzel acquired 125,000 employee stock options with an exercise price of $2.33.
- These options vest in three equal installments beginning on March 12, 2031.
- Following the reported transaction, Hartzel beneficially owns 152,211 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Positives
- The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of regulatory compliance for company insiders and provide transparency into their transactions in the company's securities.
Stakeholder Impact
- The acquisition of stock options by a company executive can influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/13/2024 | Date of transaction: William Hartzel acquired employee stock options. |
| 03/12/2031 | Employee stock options vest in three equal installments beginning on this date. |
| 03/15/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.